Applications for e Liver Meeting Abstract Ads are accepted during e regular abstract submission period. is does not apply to late-breaking abstracts. For more information Abstract Ads and reimbursement policies, visit Travel and Memorial ads or send an email to [email protected] e Liver Meeting is going virtual! Join us for e Liver Meeting Digital Experience (TLMdX) to access groundbreaking science, exchange ideas wi leading clinicians and researchers, and network wi your peers — all from e comfort of your home or office. e Best of e Liver Meeting highlights key presentations from e meeting and provides insights for patient care and ongoing research. Sum y slide ks are provided by topic. e Liver Meeting ePosters. View select ePosters from e Liver Meeting . 30, · ust 1 is fast approaching and it will be an exciting and memorable day for many of our members who submitted abstracts to e Liver Meeting . ision notifications will be sent out at day to each of e pri y au ors for e record number of 3331 abstracts. Regardless of e stage of your career – established researcher, trainee. Diversity Workshop: Social In ation: Solution-based Responses to Disparities in Liver Diseases and Liver Transplantation presented at e Liver Meeting . e Diversity and Inclusion Committee promotes heal disparities research and efforts to improve heal outcomes among e nic and racial groups who carry a higher burden of liver disease. e Liver Meeting Digital Experience AASLD Foundation Abstract Ads. AASLD Foundation Abstract Ads recognize excellence and promote e professional development of young investigators. Class of . In , AASLD Foundation will recognize 61 investigators who have submitted promising research for presentation at TLMdX. e Digital ILC will take place on 27-29 ust . An EASL in ative event for e liver community to connect and learn via cutting-edge content. Apr 23, · Abstracts of e International Liver Congress TM — 52nd Annual meeting of e European Association for e Study of e Liver 19-23 April • Amsterdam, e Ne erlands. Volume 66, Issue 1, Supplement, Pages S1-S876 () Previous vol/issue. Next vol/issue. 04, · e Liver Meeting abstract supplement, in full text, is available as a PDF, and online in a special issue of Hepatology. Late-breaking Abstracts. Late-breaking abstracts will be available on ober 20 at am ET. Meeting Event Link. Posted by Latest Update Feb 12, . 03, · LINKÖPING, Sweden. ober 3, – AASLD is e leading organization of scientists and heal care professionals committed to preventing and curing liver disease.. Two abstracts highlighting e power of AMRA’s technology have been accepted by AASLD for presentation at e Liver Meeting in Boston, Massachusetts. AMRA will present key insights and findings on e . 1 Increased Access to Liver Transplantation for Patients wi Acute on Chronic Liver Failure After Implementation of Share 35 Rule: An Analysis From e UNOS Database. Sobia Laique 1, Nan Zhang 2, Winston R. Hewitt 3, Jasmohan S. Bajaj 4, Hugo E. Vargas 1 (1) Division of Gastroenterology and Hepatology, o Clinic Arizona, (2) Division of Heal Sciences Research, o Clinic Arizona, (3. e Liver Meeting Abstract Submission Guide Submitting an abstract to e Liver Meeting can be easy. Just follow e steps outlined below. If at any point you need to leave is process, simply SAVE your work. You can pick up where you left off at. Click on e article title to read more. Visit e ILC website!. e International Liver Congress is e annual EASL meeting, and e flagship event in EASL’s educational calendar.. Every year in April, scientific and medical experts from a broad range of fields including hepatology, gastroenterology, internal medicine, cell biology, transplant surgery, infectious diseases, microbiology and virology, pharmacology. e Liver Meeting 2021 - e 72nd Annual Meeting of e American Association for e Study of Liver Diseases (AASLD) - 2021, United States (37724) Past Events. e Liver Meeting - e 70 Annual Meeting of e American Association for e Study of Liver Diseases (AASLD) - 08-12 , Boston, MA, United States (3 76). Pol et al Abstract 0197 ANRS CO22 Cohort:1960 (all races) HBeAg+/-patients who received tenofovir (75) or entecavir (885) followed-up for a mean of in 45 mon s ETV Log-rank, P=0.321 TDF 0.077 e 0.086 PAGE-B Cohort: 1935 Caucasian adults HBeAg+/-wi or wi out compensated cirrhosis on ETV (n=772) or TDF (n=1163) Papa eodorediset al Abstract. 02, · Inventiva announces e additional acceptance of two late-breaking abstracts at e AASLD e Liver Meeting Digital Experience PRESS RELEASE GlobeNewswire . . 02, · ese ree abstracts complement Inventiva’s presence at e AASLD e Liver Meeting Digital Experience , where Inventiva had already been selected for an oral plenary presentation of e. 11, · e CONFIRM abstract was also selected by AASLD for inclusion in its prestigious Best of e Liver Meeting educational program in e portal hypertension/cirrhosis category. SIG programs are scheduled roughout e Liver Meeting and feature 2- or 4-hour session on topics of interest to each SIG (see Table 3). You don’t need to be a member of a SIG to attend its program, but consider signing up for a SIG so you can receive emails about eir activities and eventually get involved in SIG leadership. 25, · Date & Time: Sunday, ember , – 8:00 am. PBI-4050 Reverses Metabolic Dysregulation Induced by a High Fat Diet in a Mouse Model of Non-Alcoholic Fatty Liver Disease. Abstract : 2136. Session: NAFLD and NASH erapeutics – Pharmacologic and O er. Location: Hall B, Hynes Convention Center. Date & Time: Monday, ember 11, . 01, · Madrigal Pharmaceuticals Announces ree Abstracts Accepted by e Liver Meeting Digital Experience, e American Association for e Study of Liver Diseases Meeting in ember , including Au or: Madrigal Pharmaceuticals, Inc. 02, · e Liver Meeting - Accepted Abstracts Now Available To e Public e Liver Meeting . San Francisco, CA. ember 9-13, . Welcome Message. (112) ember (1) ch (11) February (43) uary (57) (690). 01, · Madrigal Pharmaceuticals Announces ree Abstracts Accepted by e Liver Meeting Digital Experience, e American Association for e Study of Liver Diseases Meeting in ember , including Positive Data from resmetirom, MAESTRO-NAFLD-1, was initiated in ember targeting 700 patients wi non-alcoholic fatty liver disease. Samer Gawrieh (Indiana University,, USA) presented results of a phase 2 trial of e efficacy and safety of saroglitazar magnesium in patients wi non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). 6 patients wi NAFLD or NASH wi alanine aminotransferase (ALT) of 50 U/L or more (87 wi NAFLD and 19 wi biopsy-proven NASH) were randomly assigned to Au or: Laura Fee am. e international multidisciplinary forum for liver cancer specialists around e latest in ations in research and care. e ILCA Annual Conference is e leading scientific forum in e liver cancer field connecting hundreds of international participants from all related disciplines to exchange eir knowledge and best practices in general sessions, symposia, workshops and networking sessions. 12, · Laboratory for Advanced Medicine Presents New Liver Cancer Test Data at e Liver Meeting - Test's liver cancer detection is superior to current standard of care, new data supports -. e Liver Meeting : American Association for e Study of Liver Diseases (AASLD): Read clinically focused news coverage of key developments from AASLD . Abstract Submission Deadline. 15, 31st, e 3rd, at :00 AM (Japan time zone) ABSTRACT SUBMISSION HAS CLOSED ank you to all who submitted eir abstracts for APPLE . Pre-Registration Deadline [Early Bird] 15, 31, [Regular] y , y 31, . 11, · Enanta Pharmaceuticals Announces Poster Presentations at e Liver Meeting Business Wire WATERTOWN, Mass. ember 11, Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage. 29, · Presentations at e Liver Meeting Digital Experience include: NASH. Oral presentations. Sunday, ember 15, – :30.m. ET Evaluation of obeticholic acid efficacy in patients wi NASH who were monitored using noninvasive tests: a post hoc analysis of e REGENERATE trial (Abstract 70) Naim Alkhouri, Arun J. Sanyal, Vlad Ratziu, y Rinella, Rohit Au or: Intercept Pharmaceuticals, Inc. 21, · WASHINGTON – Nonalcoholic fatty liver disease (NAFLD) is a complex disease at involves multiple systems, and several standout abstracts at e annual meeting of e American Association for e Study of Liver Diseases emphasized e importance of multisystem management and e potential of combination erapies, Kymberly D. Watt, MD, said during e final debrief. . Collagen type IV remodeling gender-specifically predicts mortality in 2 ompensated liver cirrhosis. Compartmentalization of immune response and microbial translocation in ompensated cirrhosis. Left_Ventricular_Longitudinal_Contractility_Predicts_Acute-on-Chronic_Liver_Failure_Development. 13, · LINKÖPING, Sweden, . 13, /PRNewswire/ AMRA Medical's research is regarded as highly valuable by AASLD. e abstract titled . Exhibitors who have paid for e Liver Meeting have e option to carry overpayments to e Liver Meeting 2021 or receive a full refund. Exhibitors who choose to transfer payments to e Liver Meeting 2021 will receive e benefits below as a ank you for showing loyal partnership to AASLD: Lock-in e Liver Meeting exhibit boo pricing. 28, · Five-year analysis of long-term Ocaliva treatment in patients wi PBC selected for inclusion in ‘Best of e Liver Meeting’ abstracts. NEW YORK 28, (GLOBE NEWSWIRE) . e Liver Meeting is an annual event held by e American Association for e Study of Liver Diseases (AASLD) at ga ers over 9,500 hepatologists and hepatology heal professionals across. 13, · 13 ember . AMRA Medical Abstract Selected for AASLD’s Best of e Liver Meeting Showcase. 02, · Inventiva announces e additional acceptance of two late-breaking abstracts at e AASLD e Liver Meeting Digital Experience . 02.11. 08:00. At e end of . 11, · 89bio Announces Presentations of BIO89- 0 Data at e Liver Meeting SAN FRANCISCO and HERZLIYA, Israel, . 11, (GLOBE NEWSWIRE) 89bio, Inc. (Nasdaq: ETNB), a clinical-stage. 02, · ese ree abstracts complement Inventiva’s presence at e AASLD e Liver Meeting Digital Experience , where Inventiva had already been selected for an oral plenary presentation of e NATIVE Phase IIb clinical trial results, including new data on F2/F3 patients. e details of e various presentations are as follows. 22, · VBI Vaccines Announces Late-Breaker Poster Presentation at e Liver Meeting . ober 22, 08:00 AM Eastern Daylight Time. today announced at e company’s abstract . 13, · reporting from e liver meeting BOSTON – For almost half of patients wi nonalcoholic steatohepatitis (NASH), bariatric surgery does not resolve severe fibrosis, even after significant weight loss and resolution of multiple metabolic comorbidities, according to investigators. 01, · CONSHOHOCKEN, Pa. 01, (GLOBE NEWSWIRE) Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), announced today at, based on data from studies wi MGL-3196 (resmetirom), ree posters and an oral presentation of ese data will be presented at e Liver Meeting Digital Experience, e American Association for e Study of Liver Diseases Meeting in . 08, · VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced at its abstract highlighting data from e Phase 3 program evaluating Sci-B-Vac, e company’s 3-antigen prophylactic hepatitis B (HBV) vaccine, was accepted for e-poster presentation at e American . Background/Purpose: Majority of D Ds, including me otrexate (MTX), leflunomide (LEF) and sulfasalazine (SSZ) arebelieved to be hepatotoxic, causing liver fibrosis. However, e clinical findings were inconsistent. Anultrasound(US)-based transient elastography (TE) and shear-wave elastography (SWE) has become apromising tool in detecting liver fibrosis and fatty liver. Our study aims.